Advertisement

Comparative Analysis of SNP in Estrogen-metabolizing Enzymes for Ovarian, Endometrial, and Breast Cancers in Novosibirsk, Russia

  • Lyudmila F. Gulyaeva
  • Olga N. Mikhailova
  • Vladimir O. PustyInyak
  • Inessa V. KimIV
  • Alexei V. Gerasimov
  • Sergey E. Krasilnikov
  • Maxim L. Filipenko
  • Eugene V. Pechkovsky
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

Summary

We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers. Significant differences (OR = 2.34, p = 0.0002) in the allele distributions for CYP1A1 M1 polymorphism between patients with BC (n = 118) and controls (n = 180) were found. No significant difference in both genotype and allele distributions for CYP1A1 polymorphisms in patients with OC (n = 96) and EC (n = 154) was observed. Remarkable differences in the allele and genotype distributions for CYP1A2*1F polymorphism in patients with BC or OC were found (OR = 0.26, p = 0.0000005 and OR = 0.34, p = 0.00000002). There were no differences for this polymorphism in women with EC. In patients with BC no significant differences were found in genotype and allele distributions for R264C polymorphism in the CYP19 gene. The frequency of a mutant CYP19 heterozygote genotype C/T was higher in patients with OC and EC compared with healthy women (OR = 3.87, p = 0.001 and OR = 3.73, p = 0.0004, respectively). Comparison of allele frequencies revealed a deficiency of an allele A of SULT1A1*2 in patients with OC (OR = 0.64, p = 0.019) compared with controls. No differences were found in the genotype and allele distributions for SULT1A1 polymorphism between patients with BC and EC and controls. In addition, there were no difference in allele and genotype distributions for CYP1B1 119G→T polymorphism between BC and control. In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.

Keywords

Endometrial Cancer Allele Distribution CYP19 Gene Hormonal Carcinogenesis SULT1A1 Polymorphism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    White R, Parker MJ (1998) Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 5:1–14.CrossRefGoogle Scholar
  2. 2.
    Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86: 225–230.PubMedCrossRefGoogle Scholar
  3. 3.
    Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocrine Rew 19:593–607.CrossRefGoogle Scholar
  4. 4.
    Anderson E (2001) Ovarian steroids and control of proliferation in the normal human breast. Breast 4:273–278.CrossRefGoogle Scholar
  5. 5.
    Doisneau-Sixou SF, Sergio CM, Carroll JS, et al. (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10:179–186.PubMedCrossRefGoogle Scholar
  6. 6.
    Bulun SE, Sebastian S, Takayama K, et al. (2003) The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86:219–224.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115–124.PubMedCrossRefGoogle Scholar
  8. 8.
    Strott CA (2002) Sulfonation and molecular action. Endocr Rev 23:703–732.PubMedCrossRefGoogle Scholar
  9. 9.
    Kawajiri K, Nakachi K (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P450 1A1 gene. FEBS Lett 263:131–133.PubMedCrossRefGoogle Scholar
  10. 10.
    Goodman MT, Sachse C, Bhambra U, et al. (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68–76.CrossRefGoogle Scholar
  11. 11.
    Bailey LR, Roodi N, Dupont WD, Parl FF (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58:5038–5041.PubMedGoogle Scholar
  12. 12.
    Raftogianis R, Creveling C, Weinshilboum R, Weisz J (2000) Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 27:113–124.PubMedGoogle Scholar
  13. 13.
    Kagawa N, Hori H, Waterman MR, Yoshioka S (2004) Characterization of stable human aromatase expressed in E. coli. Steroids 69:235–243.Google Scholar
  14. 14.
    Huang CS, Shen CY, Chang KJ, et al. (1999) Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer 80:1838–1843.PubMedCrossRefGoogle Scholar
  15. 15.
    Li Yu, Millikan RC, Bell DA, et al. (2004) Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res 6:R460–R473.PubMedCrossRefGoogle Scholar
  16. 16.
    Long JR, Egan KM, Dunning L, et al (2006) Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 16:237–243.PubMedCrossRefGoogle Scholar
  17. 17.
    Ma CX, Adjei AA, Salavaggione OE, Coronel J (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65:11071–11082.PubMedCrossRefGoogle Scholar
  18. 18.
    Mikhailova ON, Gulyaeva LF, Prudnikov AV, et al. (2006) Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 6:189–193.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanna IH, Dawling S, Roodi N, et al. (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440–3444.PubMedGoogle Scholar
  20. 20.
    Shimada T, Watanabe J, Kawajiri K, et al. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20:1607–1614.PubMedCrossRefGoogle Scholar
  21. 21.
    Rylander-Rudqvist T, Wedren S, Granath F, et al. (2003) Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24:1533–1539.PubMedCrossRefGoogle Scholar
  22. 22.
    Sasaki M, Tanaka Y, Kaneuchi M, et al. (2003) CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res 63:3913–3918.PubMedGoogle Scholar
  23. 23.
    Sellers TA, Schildkraut JM, Pankratz VS, et al. (2005) Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:2536–2543.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Lyudmila F. Gulyaeva
    • 1
  • Olga N. Mikhailova
  • Vladimir O. PustyInyak
  • Inessa V. KimIV
  • Alexei V. Gerasimov
  • Sergey E. Krasilnikov
  • Maxim L. Filipenko
  • Eugene V. Pechkovsky
  1. 1.Insitute of Molecular Biology and BiophysicsAcademy of Medical SciencesNovosibirskRussia

Personalised recommendations